Biotechnology Update: Overview of Monoclonal Antibodies in the Diagnosis and Therapy of Cancer

References

• Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495–497
   PubMed Web of Science ®Google Scholar
• Nadler L M, Stashenko P, Hardy R, et al. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res 1980; 40: 3147–3154
   PubMed Web of Science ®Google Scholar
• Jain K. Delivery of novel therapeutic agents in tumors: Physiological barriers and strategies. J Natl Cancer Inst 1989; 81: 570–576
   PubMed Web of Science ®Google Scholar
• Brown S L, Miller R A, Horning SJ, et al. Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon. Blood 1989; 73: 651–661
   PubMed Web of Science ®Google Scholar
• Foon K A, Schroff R W, Bunn PA, et al. Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia. Blood 1985; 64: 1085–1094
   Web of Science ®Google Scholar
• Dillman R O, Shawler D L, Dillman J B, Roystan I. Therapy of chronic lymphocytic leukemia and cutaneous T cell lymphoma with T101 monoclonal antibody. J Clin Oncol 1984; 2: 881–891
   PubMed Web of Science ®Google Scholar
• Schroff R W, Foon K A, Beatty SM, et al. Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res 1984; 45: 879–885
   Web of Science ®Google Scholar
• Carrasquillo J A, Kroh H A, Beaumier PL, et al. Diagnosis and therapy of solid tumors with radiolabeled antibodies and immune fragments. Cancer Treat Rep 1984; 68: 317–327
   PubMedGoogle Scholar
• Sears H G, Herlyn D, Steplewski Z, Koprowski H. Effects of monoclonal antibody immunotherapy in patients with gastrointestinal adenocarcinoma. J Biol Resp Modif 1984; 3: 138–150
   PubMedGoogle Scholar
• De Nardo S J, O'Grady L F, Anderson L E, Macey DJ. Successful serial radiotherapy in spite of HAMA response. J Nucl Med 1989; 30: 827, Abst 410
   Google Scholar
• Hale G, Clark M R, Marcus R, et al. Remission induction in non-Hodgkin's lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet 1988; 2(8625)1394–1398
   PubMed Web of Science ®Google Scholar
• Foon KA. Biological response modifiers: The new immunotherapy. Cancer Res 1989; 49: 1621–1639
   PubMed Web of Science ®Google Scholar
• Waldmann T A, Longo D L, Leonard WJ, et al. Interleukin-2 receptor (Tac antigen) expression in HTLV-I-associated adult T-cell leukemia. Cancer Res 1985; 45: 4559s–4562s
   PubMed Web of Science ®Google Scholar
• Vaickus L, Jones V E, Morton C, et al. Antiproliferative mechanism of anti-class II monoclonal antibodies. Cell Immunol 1989; 119: 445–458
   PubMed Web of Science ®Google Scholar
• Garcia C F, Lowder J, Meeker RC, et al. Differences in ‘host infiltrates’ among lymphoma patients treated with anti-idiotype antibodies: correlation with treatment response. J Immunol 1985; 135: 4252
   PubMed Web of Science ®Google Scholar
• Wilbur D S, Hadley S W, Hylarides MD, et al. Development of a stable radioiodinating reagent to label monoclonal antibodies for radiotherapy of cancer. J Nucl Med 1989; 30: 216–226
   PubMed Web of Science ®Google Scholar
• Mach J P, Bucheggar F, Forni M, et al. Use of radiolabeled monoclonal anti-CEA antibodies for detection of human carcinomas by external photoscanning and tomoscintigraphy. Immunol Today 1981; 2: 239–249
   PubMedGoogle Scholar
• Epenetos A A, Mather S, Granowska M, et al. Targeting of iodine-123-labeled tumor-associated monoclonal antibodies to ovarian, breast and gastrointestinal tumors. Lancet 1982; 2: 999–1004
   PubMed Web of Science ®Google Scholar
• Larson S M, Carrasquillo J A, Khron KA, et al. Localization of 131I-labeled p97 specific Fab fragments in human melanomas as a basis for radiotherapy. J Clin Invest 1983; 72: 2101–2114
   PubMed Web of Science ®Google Scholar
• Carrasquillo J A, Bunn PA, Jr, Kennan AM, et al. Radioimmuno-detection of cutaneous T-cell lymphoma with 111In-labeled T101 monoclonal antibody. N Engl J Med 1985; 315: 673–679
   Google Scholar
• Carrasquillo J A, Abrams P G, Schroff RW, et al. Effect of 111In-9.2.27 monoclonal antibody dose on the imaging of metastatic melanoma. J Nucl Med 1988; 29: 37–47
   Google Scholar
• Kennan A M, Weinstein J N, Carrasquillo J, et al. Immunolym-phoscintigraphy and the dose dependence of 111In-labeled T101 monoclonal antibody in patients with cutaneous T-cell lymphoma. Cancer Res 1987; 47: 6093–6099
   PubMed Web of Science ®Google Scholar
• Fritzberg A R, Abrams P G, Beaumier PL, et al. Specific and stable labeling of antibodies with technetium-99m with a diamide dithiolate chelating agent. Proc Natl Acad Sci (USA) 1988; 85: 4025–4029
   PubMed Web of Science ®Google Scholar
• Feun L, Kotler J, Serafini A, et al. Anti-melanoma Tc 99m FAB antibody for imaging metastatic melanoma (MM). Proc Am Soc Clin Oncol 1988; 7: 249
   Google Scholar
• Schlom J, Colcher D, Roselli M, et al. Tumor targeting with monoclonal antibody B72.3. Nucl Med Biol 1989; 16: 137–142
   Web of Science ®Google Scholar
• Woo D V, Li D, Mattis J A, Steplewski Z. Selective chromosomal damage and cytotoxicity of 125I-labeled monoclonal antibody 17–1a in human cancer cells. Cancer Res 1989; 49: 2952–2958
   PubMed Web of Science ®Google Scholar
• Beirwaltes WH. Radioimmunotherapy of cancer: historical prospectives and prospects for the future. Text of talk delivered at the NATO Conference on Radiolabeled Monoclonal Antibodies for Imaging and Therapy: Potential, Problems and Prospects. BargaItaly 1986
   Google Scholar
• Order S E, Stillwagon G B, Klein JL, et al. Iodine-131-antiferritin, a new treatment modality in hepatomas: a radiation therapy oncology group study. J Clin Oncol 1985; 3: 1573–1582
   PubMed Web of Science ®Google Scholar
• Lenhard R E, Order S E, Spunberg J J, Asbell S O, Leibel DA. Istopic immunoglobulin: a new systemic therapy for advanced Hodgkin's disease. J Clin Oncol 1985; 3: 1296–1300
   PubMed Web of Science ®Google Scholar
• Order S E, Klein J L, Leicher PK, et al. 90Yttrium antiferritin—a new therapeutic radiolabeled antibody. Int J Radiat Oncol Biol Phys 1986; 12: 277–281
   PubMed Web of Science ®Google Scholar
• Larson S M, Raubitschek A, Reynolds JC, et al. Comparison of bone marrow dosimetry and toxic effect of high dose iodine-131-labeled monoclonal antibodies administered to man. Nucl Med Biol 1989; 16: 153–158
   Web of Science ®Google Scholar
• De Nardo S J, De Nardo G L, O'Grady LF, et al. Treatment of B cell malignancies with 131I Lym-1 monoclonal antibodies. Int J Cancer 1988; 96–101, Suppl 3
   PubMed Web of Science ®Google Scholar
• Epenetos A A, Munro A J, Stewart S, et al. Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies. J Clin Oncol 1987; 5: 1890–1899
   PubMed Web of Science ®Google Scholar
• Finkler N J, Muto M G, Kassis AI, et al. Intraperitoneal radiolabeled OC 125 in patients with advanced ovarian cancer. Gynecol Oncol 1989; 34: 339–344
   PubMed Web of Science ®Google Scholar
• Rosen S, Zimmer A M, Goldman-Neiken R, et al. Radioimmuno-detection and radioimmunotherapy of cutaneous T-cell lymphomas using an 131I-labeled monoclonal antibody: an Illinois Cancer Council Study. J Clin Oncol 1987; 5: 562–573
   PubMed Web of Science ®Google Scholar
• Press O W, Eary J F, Badger CC, et al. Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J Clin Oncol 1989; 7: 1027–1038
   PubMed Web of Science ®Google Scholar
• Cheung N-KV, Munn D, Kushner BH, et al. Targeted radiotherapy and immunotherapy of human neuroblastoma with GD2 specific monoclonal antibodies. Nucl Med Biol 1989; 16: 111–120
   Web of Science ®Google Scholar
• Halpern S, Parker B A, Vassos A, Frincke J. 90Yttrium (90Y) anti-idiotype monoclonal antibody therapy of non-Hodgkin's lymphoma. J Nucl Med 1989; 30: 778, Abst 206
   Google Scholar
• Hnatowich D J, Stevens S, Kinders RJ, et al. Intraperitoneal Yttrium-90 immunotherapy in ovarian cancer patients. J Nucl Med 1989; 30: 828, Abst 413
   Google Scholar
• Laurent G, Pris J, Farcel J-P. Effects of therapy with T101 ricin A-chain immunotoxin in two leukemia patients. Blood 1986; 67: 1680–1687
   PubMed Web of Science ®Google Scholar
• Nadler L, Breitmeyer J, Coral F, et al. Anti-B4 blocked ricin immunotherapy for patients with B cell malignancies: Phase I trial of bolus infusions. Blood 1989; 74: 121a, Suppl 1
   Google Scholar
• Weiner L M, O'Dwyer J, Kitson J, et al. Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A chain immunoconjugate. Cancer Res 1989; 49: 4062–4067
   PubMed Web of Science ®Google Scholar
• Spitler L, del Rio M, Khentigan A, et al. Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody ricin A chain immunotoxin. Cancer Res 1987; 47: 1717–1723
   PubMed Web of Science ®Google Scholar
• Hertler A A, Schlossman D M, Borowitz MJ, et al. A Phase I study of T101 -ricin A chain immunotoxin in refractory chronic lymphocytic leukemia. J Biol Resp Modif 1988; 7: 97–113
   PubMedGoogle Scholar
• Hertler A A, Frankel AE. Immunotoxins: A clinical review of their use in the treatment of malignancies. J Clin Oncol 1989; 12: 1932–1942
   Google Scholar
• Dillman R O, Johnson D E, Shawler DL. Comparisons of drugs and toxin immunoconjugates. Antibody, Immunocon Radiopharm 1988; 1: 65–77
   Google Scholar
• Pietersz G A, Smyth M J, Kanells J, et al. Preclinical and clinical studies with a variety of immunoconjugates. Antibody, Immunoconj Radiopharm 1988; 1: 79–103
   Google Scholar
• Morgan A C, Sullivan W, Graves S, Woodhouse CS. Murine monoclonal IgG3 to human colorectal tumor-associated antigens: enhancement of antibody-dependent cell-mediated cytotoxicity by interleukin-2. Cancer Res 1989; 49: 2773–2776
   PubMed Web of Science ®Google Scholar
• Schultz K R, Klarnet J P, Peace DJ, et al. Adoptive transfer of lymphokine-activated killer (LAK) cells augments monoclonal antibody eradication of murine lymphoma without toxicity. Proc Am Assoc Can Res 1989; 30: 353, Abst 1441
   Google Scholar
• Mufson R A, Aghajanian J, Wang G, et al. Macrophage colony-stimulating factor enhances monocyte and macrophage antibody-dependent cell-mediated cytotoxicity. Cell Immunol 1989; 119: 182–192
   PubMed Web of Science ®Google Scholar
• Golde DW. In vivo studies with granulocyte-macrophage colony-stimulating factors. Ann Int Med 1989; 110: 297–303
   PubMedGoogle Scholar
• Wing E J, Magee D M, Whiteside, et al. Recombinant human granulocyte/macrophage colony-stimulating factor enhances monocyte cytotoxicity and secretion of TNF-alpha and interferon in cancer patients. Blood 1989; 73: 643–646
   PubMed Web of Science ®Google Scholar
• Biddle W, Pancook J, Foon KA, et al. Lym-1 mediated antibody dependent cellular cytotoxicity against human B lymphoma targets is enhanced by recombinant IL-2. Cancer Res 1990; 50: 2991–2996
   PubMed Web of Science ®Google Scholar
• Vaickus L, Biddle W, Cemerlic D, Foon KA. Gamma-interferon augments Lym-1 dependent, granulocyte-mediated tumor lysis. Blood 1990; 75: 2408–2416
   PubMed Web of Science ®Google Scholar
• Weiner L M, Steplewski Z, Kaprowski H, et al. Divergent dose-related effects of gamma interferon therapy on in vitro ADCC and nonspecific cytotoxicity by human peripheral blood monocytes. Cancer Res 1988; 48: 1042–1046
   PubMed Web of Science ®Google Scholar
• Herlyn D, Wettendorff M, Iliopoulos D, et al. Immunotherapy of colorectal cancer with anti-idiotypic antibodies. Proc Am Assoc Cancer Res 1988; 2: 408
   Google Scholar
• Mittelman A, Kageshita T, Kusama K, et al. A clinical trial of murine antiidiotype monoclonal antibodies to high molecular weight melanoma associated antigens. Proc Am Soc Clin Oncol 1988; 7: 248
   Google Scholar
• Press O W, Appelbaum F, Ledbetter JA, et al. Monoclonal antibody (F5 Ianti-CD20) serotherapy of human B-cell lymphomas. Blood 1987; 69: 584–591
   PubMed Web of Science ®Google Scholar
• Dillman R O, Shawler D L, Sobel RE, et al. Murine monoclonal antibody therapy in two patients with chronic lymphocytic leukemia. Blood 1982; 59: 1036–1045
   PubMed Web of Science ®Google Scholar
• Bertram J H, Gill P S, Levine AM, et al. Monoclonal antibody T101 in T cell malignancies: a clinical, pharmacokinetic, and immunologic correlation. Blood 1986; 68: 752–761
   PubMed Web of Science ®Google Scholar
• Miller Ra., Oseroff A R, Stratte P T, Levy R. Monoclonal antibody therapuetic trials in seven patients with T cell lymphoma. Blood 1983; 62: 988–995
   PubMed Web of Science ®Google Scholar
• Levy R, Miller RA. Tumor therapy with monoclonal antibodies. Fed Proc 1983; 42: 2650–2656
   PubMedGoogle Scholar
• Ritz J, Pesando J M, Sallan SE, et al. Serotherapy of acute lympho-blastic leukemia with monoclonal antibody. Blood 1981; 58: 141–152
   PubMed Web of Science ®Google Scholar
• Ball E D, Bernier G M, Cornwell GG, et al. Monoclonal antibodies to myeloid differentiation antigens: in vivo studies of three patients with acute myelogenous leukemia. Blood 1983; 62: 1203–1210
   PubMed Web of Science ®Google Scholar
• Schroff R W, Morgan A C, Woodhouse CS, et al. Monoclonal antibody therapy in malignant melanoma: factors effecting in vivo localization. J Biol Resp Modif 1987; 6: 457–472
   PubMedGoogle Scholar
• Oldham R K, Foon K A, Morgan AC, et al. Monoclonal antibody therapy of malignant melanoma: In vivo localization in cutaneous metastasis after intravenous administration. J Clin Oncol 1984; 2: 1235–1244
   PubMed Web of Science ®Google Scholar
• Vadhan-Raj S, Cordon-Cardo C, Carswell E, et al. Phase I trial of a mouse monoclonal antibody against CD3 ganglioside in patients with melanoma: Induction of inflammatory responses at tumor sites. J Clin Oncol 1988; 6: 1636–1648
   PubMed Web of Science ®Google Scholar